- | Rocket Pharmaceuticals
Latest data give Rocket clear path forward in rare CV disease Danon
While an adverse event in the high-dose cohort continues to outline the limits oh high volume AAV dosing…
- | Fountain Therapeutics
View From The Inside: What’s Shaping Biopharma In 2021 And Beyond?
About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual Outlook issue. At least two of those questions, had they been asked just a month or so later, would have surely yielded very different responses than they did in December 2019: What impact would a U.S. economic slowdown have on biopharma manufacturing, and what should biopharma do in the next three to five years to reduce risk to global supply chains posed by natural disasters?
- | GigaGen
2020 Top 10 Innovations
Enter GigaGen’s Surge platform, which uses single-cell sequencing to “capture and recreate” libraries of antibodies from blood donors.
- | Cerevance
Trial Drug Shows Promise in Treating Cognitive Impairment Associated with Schizophrenia
Last week, privately-owned Cerevance released data from a Phase Ib biomarker study of its oral compound, CVN058, evaluating the potential of the medication as a treatment for cognitive impairment associated with schizophrenia (CIAS).
- | Arrowhead Pharmaceuticals
Genetic medicines find a heartbeat
“RNA interference is often better than antibodies because of the catalytic process that you can generally use,” said Chris Anzalone, CEO of Arrowhead Pharmaceuticals. A drug like inclisiran can cut LDL cholesterol in half with only two injections per year, whereas Praluent and Repatha injections are given every 2 to 4 weeks.
- | Scynexis
Emerging fungal resistance: A hidden epidemic
Invasive fungal infections are becoming increasingly common and often pose a serious public health threat, claiming the lives of more than 1.5 million people worldwide each year.
- | Clene Nanomedicine
New Class of Drugs Harnesses Gold Nanocrystals to Heal and Protect the Brain
Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.
- | CalciMedica
Targeting Calcium Overload Could Improve Stroke Outcomes
“We are fortunate to collaborate with CalciMedica, a pharmaceutical company who specializes in developing drugs suppressing calcium overload in the immune cells,” Tvrdik said. “We share the vison that our research might help to identify an effective drug that will improve the recovery of stroke survivors.”
